N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis

Journal of Neurology

Volumn 261, Issue 12, 2014, Pages 2338-2343

  Trentini, Alessandro ^a,b   Comabella, Manuel ^c   Tintoré, Mar ^c   Koel Simmelink, Marleen J A ^a   Killestein, Joep ^a   Roos, Birthe ^a   Rovira, Alex ^d   Korth, Carsten ^e   Ottis, Philipp ^e   Blankenstein, Marinus A ^a   Montalban, Xavier ^c   Bellini, Tiziana ^b   Teunissen, Charlotte E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF FERRARA   (Italy)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HUVH   (Spain)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Axonal damage; Cerebrospinal fluid; Multiple sclerosis; N Acetylaspartic acid; Neurofilaments

Indexed keywords

BIOLOGICAL MARKER; N ACETYLASPARTIC ACID; ASPARTIC ACID; N-ACETYLASPARTATE; NEUROFILAMENT PROTEIN;

ARTICLE; AXONAL INJURY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISABILITY; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS SEVERITY SCORE; NEUROFILAMENT; NEUROLOGIC DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; ADULT; ANALOGS AND DERIVATIVES; CEREBROSPINAL FLUID; DISEASE COURSE; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; NERVE FIBER; PATHOLOGY;

ADULT; ASPARTIC ACID; AXONS; BIOLOGICAL MARKERS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; PROGNOSIS;

EID: 84920964477     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7507-4     Document Type: Article

References (22)

1. Tallantyre EC, Bø L, Al-Rawashdeh O et al (2009) Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain 132:1190–1199
2. Thompson AJ, Kermode AG, Wicks D et al (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53–62
3. Teunissen CE, Iacobaeus E, Khademi M et al (2009) Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 72:1322–1329
4. Montalban X, Sastre-Garriga J, Tintoré M et al (2009) A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 15:1195–1205
5. Teunissen CE, Petzold A, Bennett JL et al (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73:1914–1922
6. Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987:25–31
7. Petzold A, Altintas A, Andreoni L et al (2010) Neurofilament ELISA validation. J Immunol Methods 352:23–31
8. Koel-Simmelink MJA, Vennegoor A, Killestein J et al (2014) The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J Immunol Methods 402:43–49
9. Kuhle J, Leppert D, Petzold A et al (2011) Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 76:1206–1213
10. Khalil M, Enzinger C, Langkammer C et al (2013) CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 19:436–442
11. Norgren N, Sundström P, Svenningsson A et al (2004) Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 63:1586–1590
12. Kuhle J, Malmeström C, Axelsson M et al (2013) Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 128:e33–e36
13. Romme Christensen J, Börnsen L, Khademi M et al (2013) CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 19:877–884
14. Petzold A, Eikelenboom MJ, Keir G et al (2005) Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 76:206–211
15. Jasperse B, Jakobs C, Eikelenboom MJ et al (2007) N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol 254:631–637
16. Kuhle J, Plattner K, Bestwick JP et al (2013) A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 19:1597–1603
17. Petzold A, Eikelenboom MI, Keir G et al (2006) The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler 12:325–328
18. Llufriu S, Kornak J, Ratiney H et al (2014) Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol 71:840–847
19. Salzer J, Svenningsson A, Sundström P (2010) Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 16:287–292
20. Teunissen C, Menge T, Altintas A et al (2013) Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 19:1802–1809
21. Eikelenboom MJ, Petzold A, Lazeron RHC et al (2003) Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 60:219–223
22. Ghonemi MO, Rabah AA, Saber HM, Radwan W (2013) Role of Phosphorylated Neurofilament H as a diagnostic and prognostic marker in traumatic brain injury. Egypt J Crit Care Med 1:139–144